VM-26 in gastric cancer - A Southwest Oncology Group study

Jeffrey L. Berenberg; Catherine Tangen; John S. Macdonald; Bart Barlogie; Leslie Rogers Laufman

doi:10.1007/BF00874433

VM-26 in gastric cancer - A Southwest Oncology Group study

Jeffrey L. Berenberg, Catherine Tangen, John S. Macdonald, Bart Barlogie, Leslie Rogers Laufman

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The Southwest Oncology Group conducted a trial of VM-26 (teniposide) in patients with advanced gastric cancer. VM-26 60 mg/m² IV infusion over 30-45 minutes was given daily for 5 days every 21 days. Twentyone eligible patients with measurable disease and a SWOG performance status of 0-2 were analyzed for response and toxicity. Partial responses were seen in 2 of the 21 eligible patients (9.5%). Median survival was 3.8 months. Severe or life-threatening toxicity was observed in 13/21 (62%) patients. This included two drug related deaths related to neutropenic sepsis and seven other patients with grade 4 granulocytopenia (< 500/mm³). Liver dysfunction and hypotension were seen less often and were not dose limiting. Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide) in advanced gastric cancer.

Original language	English
Pages (from-to)	333-334
Number of pages	2
Journal	Investigational New Drugs
Volume	11
Issue number	4
DOIs	https://doi.org/10.1007/BF00874433
State	Published - Dec 1993
Externally published	Yes

Keywords

gastric cancer
teniposide

Access to Document

10.1007/BF00874433

Cite this

@article{f0811b27b12d4f60a96b10034426a434,

title = "VM-26 in gastric cancer - A Southwest Oncology Group study",

abstract = "The Southwest Oncology Group conducted a trial of VM-26 (teniposide) in patients with advanced gastric cancer. VM-26 60 mg/m2 IV infusion over 30-45 minutes was given daily for 5 days every 21 days. Twentyone eligible patients with measurable disease and a SWOG performance status of 0-2 were analyzed for response and toxicity. Partial responses were seen in 2 of the 21 eligible patients (9.5\%). Median survival was 3.8 months. Severe or life-threatening toxicity was observed in 13/21 (62\%) patients. This included two drug related deaths related to neutropenic sepsis and seven other patients with grade 4 granulocytopenia (< 500/mm3). Liver dysfunction and hypotension were seen less often and were not dose limiting. Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide) in advanced gastric cancer.",

keywords = "gastric cancer, teniposide",

author = "Berenberg, \{Jeffrey L.\} and Catherine Tangen and Macdonald, \{John S.\} and Bart Barlogie and Laufman, \{Leslie Rogers\}",

year = "1993",

month = dec,

doi = "10.1007/BF00874433",

language = "English",

volume = "11",

pages = "333--334",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - VM-26 in gastric cancer - A Southwest Oncology Group study

AU - Berenberg, Jeffrey L.

AU - Tangen, Catherine

AU - Macdonald, John S.

AU - Barlogie, Bart

AU - Laufman, Leslie Rogers

PY - 1993/12

Y1 - 1993/12

N2 - The Southwest Oncology Group conducted a trial of VM-26 (teniposide) in patients with advanced gastric cancer. VM-26 60 mg/m2 IV infusion over 30-45 minutes was given daily for 5 days every 21 days. Twentyone eligible patients with measurable disease and a SWOG performance status of 0-2 were analyzed for response and toxicity. Partial responses were seen in 2 of the 21 eligible patients (9.5%). Median survival was 3.8 months. Severe or life-threatening toxicity was observed in 13/21 (62%) patients. This included two drug related deaths related to neutropenic sepsis and seven other patients with grade 4 granulocytopenia (< 500/mm3). Liver dysfunction and hypotension were seen less often and were not dose limiting. Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide) in advanced gastric cancer.

AB - The Southwest Oncology Group conducted a trial of VM-26 (teniposide) in patients with advanced gastric cancer. VM-26 60 mg/m2 IV infusion over 30-45 minutes was given daily for 5 days every 21 days. Twentyone eligible patients with measurable disease and a SWOG performance status of 0-2 were analyzed for response and toxicity. Partial responses were seen in 2 of the 21 eligible patients (9.5%). Median survival was 3.8 months. Severe or life-threatening toxicity was observed in 13/21 (62%) patients. This included two drug related deaths related to neutropenic sepsis and seven other patients with grade 4 granulocytopenia (< 500/mm3). Liver dysfunction and hypotension were seen less often and were not dose limiting. Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide) in advanced gastric cancer.

KW - gastric cancer

KW - teniposide

UR - https://www.scopus.com/pages/publications/0027742338

U2 - 10.1007/BF00874433

DO - 10.1007/BF00874433

M3 - Article

C2 - 8157475

AN - SCOPUS:0027742338

SN - 0167-6997

VL - 11

SP - 333

EP - 334

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

VM-26 in gastric cancer - A Southwest Oncology Group study

Abstract

Keywords

Access to Document

Fingerprint

Cite this